Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong Yin Zhang, Daniela Matei

Research output: Contribution to journalArticle

Abstract

Tissue transglutaminase (TG2) is a multifunctional protein with enzymatic, GTP-ase, and scaffold properties. TG2 interacts with fibronectin (FN) through its N-terminus domain, stabilizing integrin complexes, which regulate cell adhesion to the matrix. Through this mechanism, TG2 participates in key steps involved in metastasis in ovarian and other cancers. High-throughput screening identified several small molecule inhibitors (SMI) for the TG2/FN complex. Rational medicinal chemistry optimization of the hit compound (TG53) led to second-generation analogues (MT1-6). ELISA demonstrated that these analogues blocked TG2/FN interaction, and bio-layer interferometry (BLI) showed that the SMIs bound to TG2. The compounds also potently inhibited cancer cell adhesion to FN and decreased outside-in signaling mediated through the focal adhesion kinase. Blockade of TG2/FN interaction by the small molecules caused membrane ruffling, delaying the formation of stable focal contacts and mature adhesions points and disrupted organization of the actin cytoskeleton. In an in vivo model measuring intraperitoneal dissemination, MT4 and MT6 inhibited the adhesion of ovarian cancer cells to the peritoneum. Pretreatment with MT4 also sensitized ovarian cancer cells to paclitaxel. The data support continued optimization of the new class of SMIs that block the TG2/FN complex at the interface between cancer cells and the tumor niche.

Original languageEnglish (US)
Pages (from-to)1057-1068
Number of pages12
JournalMolecular cancer therapeutics
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Fingerprint

Fibronectins
Ovarian Neoplasms
Cell-Matrix Junctions
Interferometry
Focal Adhesion Protein-Tyrosine Kinases
Neoplasms
Focal Adhesions
Pharmaceutical Chemistry
Peritoneum
Paclitaxel
Guanosine Triphosphate
Actin Cytoskeleton
Cell Adhesion
Integrins
transglutaminase 2
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Membranes
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. / Sima, Livia Elena; Yakubov, Bakhtiyor; Zhang, Sheng; Condello, Salvatore; Grigorescu, Arabela A.; Nwani, Nkechiyere G.; Chen, Lan; Schiltz, Gary E.; Arvanitis, Constandina; Zhang, Zhong Yin; Matei, Daniela.

In: Molecular cancer therapeutics, Vol. 18, No. 6, 01.06.2019, p. 1057-1068.

Research output: Contribution to journalArticle

Sima, LE, Yakubov, B, Zhang, S, Condello, S, Grigorescu, AA, Nwani, NG, Chen, L, Schiltz, GE, Arvanitis, C, Zhang, ZY & Matei, D 2019, 'Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin', Molecular cancer therapeutics, vol. 18, no. 6, pp. 1057-1068. https://doi.org/10.1158/1535-7163.MCT-18-1148
Sima, Livia Elena ; Yakubov, Bakhtiyor ; Zhang, Sheng ; Condello, Salvatore ; Grigorescu, Arabela A. ; Nwani, Nkechiyere G. ; Chen, Lan ; Schiltz, Gary E. ; Arvanitis, Constandina ; Zhang, Zhong Yin ; Matei, Daniela. / Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 6. pp. 1057-1068.
@article{6d9b282ce67d49f6a37cb2a907425898,
title = "Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin",
abstract = "Tissue transglutaminase (TG2) is a multifunctional protein with enzymatic, GTP-ase, and scaffold properties. TG2 interacts with fibronectin (FN) through its N-terminus domain, stabilizing integrin complexes, which regulate cell adhesion to the matrix. Through this mechanism, TG2 participates in key steps involved in metastasis in ovarian and other cancers. High-throughput screening identified several small molecule inhibitors (SMI) for the TG2/FN complex. Rational medicinal chemistry optimization of the hit compound (TG53) led to second-generation analogues (MT1-6). ELISA demonstrated that these analogues blocked TG2/FN interaction, and bio-layer interferometry (BLI) showed that the SMIs bound to TG2. The compounds also potently inhibited cancer cell adhesion to FN and decreased outside-in signaling mediated through the focal adhesion kinase. Blockade of TG2/FN interaction by the small molecules caused membrane ruffling, delaying the formation of stable focal contacts and mature adhesions points and disrupted organization of the actin cytoskeleton. In an in vivo model measuring intraperitoneal dissemination, MT4 and MT6 inhibited the adhesion of ovarian cancer cells to the peritoneum. Pretreatment with MT4 also sensitized ovarian cancer cells to paclitaxel. The data support continued optimization of the new class of SMIs that block the TG2/FN complex at the interface between cancer cells and the tumor niche.",
author = "Sima, {Livia Elena} and Bakhtiyor Yakubov and Sheng Zhang and Salvatore Condello and Grigorescu, {Arabela A.} and Nwani, {Nkechiyere G.} and Lan Chen and Schiltz, {Gary E.} and Constandina Arvanitis and Zhang, {Zhong Yin} and Daniela Matei",
year = "2019",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-18-1148",
language = "English (US)",
volume = "18",
pages = "1057--1068",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

AU - Sima, Livia Elena

AU - Yakubov, Bakhtiyor

AU - Zhang, Sheng

AU - Condello, Salvatore

AU - Grigorescu, Arabela A.

AU - Nwani, Nkechiyere G.

AU - Chen, Lan

AU - Schiltz, Gary E.

AU - Arvanitis, Constandina

AU - Zhang, Zhong Yin

AU - Matei, Daniela

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Tissue transglutaminase (TG2) is a multifunctional protein with enzymatic, GTP-ase, and scaffold properties. TG2 interacts with fibronectin (FN) through its N-terminus domain, stabilizing integrin complexes, which regulate cell adhesion to the matrix. Through this mechanism, TG2 participates in key steps involved in metastasis in ovarian and other cancers. High-throughput screening identified several small molecule inhibitors (SMI) for the TG2/FN complex. Rational medicinal chemistry optimization of the hit compound (TG53) led to second-generation analogues (MT1-6). ELISA demonstrated that these analogues blocked TG2/FN interaction, and bio-layer interferometry (BLI) showed that the SMIs bound to TG2. The compounds also potently inhibited cancer cell adhesion to FN and decreased outside-in signaling mediated through the focal adhesion kinase. Blockade of TG2/FN interaction by the small molecules caused membrane ruffling, delaying the formation of stable focal contacts and mature adhesions points and disrupted organization of the actin cytoskeleton. In an in vivo model measuring intraperitoneal dissemination, MT4 and MT6 inhibited the adhesion of ovarian cancer cells to the peritoneum. Pretreatment with MT4 also sensitized ovarian cancer cells to paclitaxel. The data support continued optimization of the new class of SMIs that block the TG2/FN complex at the interface between cancer cells and the tumor niche.

AB - Tissue transglutaminase (TG2) is a multifunctional protein with enzymatic, GTP-ase, and scaffold properties. TG2 interacts with fibronectin (FN) through its N-terminus domain, stabilizing integrin complexes, which regulate cell adhesion to the matrix. Through this mechanism, TG2 participates in key steps involved in metastasis in ovarian and other cancers. High-throughput screening identified several small molecule inhibitors (SMI) for the TG2/FN complex. Rational medicinal chemistry optimization of the hit compound (TG53) led to second-generation analogues (MT1-6). ELISA demonstrated that these analogues blocked TG2/FN interaction, and bio-layer interferometry (BLI) showed that the SMIs bound to TG2. The compounds also potently inhibited cancer cell adhesion to FN and decreased outside-in signaling mediated through the focal adhesion kinase. Blockade of TG2/FN interaction by the small molecules caused membrane ruffling, delaying the formation of stable focal contacts and mature adhesions points and disrupted organization of the actin cytoskeleton. In an in vivo model measuring intraperitoneal dissemination, MT4 and MT6 inhibited the adhesion of ovarian cancer cells to the peritoneum. Pretreatment with MT4 also sensitized ovarian cancer cells to paclitaxel. The data support continued optimization of the new class of SMIs that block the TG2/FN complex at the interface between cancer cells and the tumor niche.

UR - http://www.scopus.com/inward/record.url?scp=85067216919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067216919&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-18-1148

DO - 10.1158/1535-7163.MCT-18-1148

M3 - Article

C2 - 31015308

AN - SCOPUS:85067216919

VL - 18

SP - 1057

EP - 1068

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -